G.R. No. 166494 - Carlos Superdrug Corp. vs. Department of Social Welfare and Development

Case Summary (G.R. No. 166494)

Factual Background

The legislature enacted R.A. No. 9257 to expand benefits to senior citizens by amending R.A. No. 7432 and declaring a policy to strengthen the family and provide social security and welfare programs for the elderly. Section 4(a) of R.A. No. 9257 granted senior citizens a twenty percent discount on specified services and purchases, expressly including the purchase of medicines from all establishments for the exclusive use or enjoyment of senior citizens, and provided that establishments may claim such discounts as a tax deduction based on the net cost of goods sold or services rendered.

Implementing Regulations and Administrative Orders

The DSWD adopted implementing rules and regulations for R.A. No. 9257 on May 28, 2004; Rule VI, Article 8 reiterated that establishments may claim the discounts as tax deductions and stated that implementation of the tax deduction would be subject to revenue regulations of the Bureau of Internal Revenue and the approval of the DOF. The DOH issued Administrative Order No. 171 providing for a twenty percent discount on unbranded generic medicines, and later amended it by A.O. No. 177 to extend the discount to both prescription and non-prescription medicines whether branded or generic.

DOF Opinion on Tax Treatment

In response to an inquiry, the DOF issued a written opinion on July 10, 2004, distinguishing the prior tax credit scheme under R.A. No. 7432 from the tax deduction scheme under R.A. No. 9257. The DOF explained that a tax deduction reduces taxable income and thus lowers tax liability only fractionally, whereas a tax credit is a peso-for-peso reduction of tax liability. The DOF concluded that under the deduction scheme the government effectively foregoes revenue equivalent to the marginal tax rate on the deducted amount—illustratively thirty-two percent—while establishments shoulder the remaining portion of the discount.

Procedural Posture

Petitioners filed a petition for Prohibition with prayer for preliminary injunction under Rule 65, Rules of Court, challenging the constitutionality of Section 4(a) of R.A. No. 9257. The matter was heard and decided by the Supreme Court, En Banc, with Justice Azcuna as ponente. The Supreme Court dismissed the petition for lack of merit.

Petitioners' Contentions

Petitioners contended that Section 4(a) is unconstitutional on three principal grounds: first, that the statutory requirement to grant a twenty percent discount on medicines effectuates a confiscatory taking of private property in violation of Article III, Section 9 of the Constitution because the tax deduction scheme fails to provide just compensation; second, that the law violates the equal protection clause of Article III, Section 1; and third, that the law contravenes Article XIII, Section 11 by undermining the availability of essential goods and health services at affordable cost. Petitioners argued that retail mark-ups on branded medicines are often only five to ten percent, such that extending a twenty percent discount will force sales below acquisition cost and destroy capital and profit, and they offered a specific per-tablet computation using the drug Norvasc as an example.

Court's Statement of Legal Issue

The central legal issue the Court addressed was whether Section 4(a) of R.A. No. 9257, insofar as it mandates a twenty percent discount on medicines and allows reimbursement to establishments only by way of a tax deduction, effects an uncompensated taking or otherwise violates due process or equal protection, and whether the legislative means employed are a proper exercise of the State's police power in light of the Constitution's social welfare provisions.

Court's Analysis on Police Power Versus Taking

The Court recognized that the discount reduces private revenues and may impose a burden on drugstore owners, but it held that the law is a legitimate exercise of the State's police power to promote the general welfare. The Court reiterated the principle that property rights, though protected by due process, must yield when the public interest as determined by the legislature so requires, and that the power of the legislature to enact wholesome and reasonable laws for the common good is broad. The Court observed that police power differs from eminent domain and that regulatory impositions that advance public welfare do not automatically constitute compensable takings.

Court's Assessment of the Just Compensation Claim

Addressing the specific takings argument, the Court explained that the tax deduction provided by the statute is not equivalent to cash reimbursement but is a legislatively sanctioned fiscal mechanism which reduces taxable income and thereby reduces tax liability. The Court noted that a tax deduction does not offer peso-for-peso recovery and therefore does not constitute the type of just compensation required for an eminent domain taking; nonetheless, the Court found that petitioners had not shown that the statutory scheme amounted to a confiscatory taking that would warrant invalidation under the Constitution.

Court's Evaluation of Petitioners' Evidence and Economic Arguments

The Court found petitioners' economic demonstrations flawed and insufficient. It held that petitioners improperly computed loss on a per-transaction basis rather than by reference to an income statement showing sales, expenses, and net profit for a period. The Court also noted that petitioners assumed, erroneously, that all customers would be senior citizens and that the thirty-two percent figure applied directly to the amount of the discount rather than to income. The Court emphasized that petitioners had not submitted financial statements to substantiate a claim of confiscation and that the presumption of validity attends legislative acts absent convincing proof of unconstitutionality.

Business Realities, Pricing Decisions, and the Social Dimension of Property

The Court observed that pricing practices and mark-ups are business decisions and that competitive conditions may restrain a merchant's ability to increase prices.

Case Syllabus (G.R. No. 166494)

Parties and Procedural Posture

Petitioners were domestic corporations and proprietors operating drugstores who filed a petition for Prohibition with Prayer for Preliminary Injunction under Rule 65, Rules of Court.
Respondents were the Department of Social Welfare and Development (DSWD), the Department of Health (DOH), the Department of Finance (DOF), the Department of Justice (DOJ), and the Department of Interior and Local Government (DILG) which were charged with implementing and enforcing the law.
Petitioners assailed the constitutionality and enforcement of Section 4(a) of R.A. No. 9257 and sought to enjoin its application to their establishments.
The case reached the Court en banc and the decision was delivered by Justice Azcuna.

Key Factual Allegations

R.A. No. 9257 was enacted to amend R.A. No. 7432 and became effective March 21, 2004.
Section 4(a) of R.A. No. 9257 granted senior citizens a twenty percent discount on purchases of medicines from all establishments for the exclusive use or enjoyment of senior citizens.
The DSWD adopted implementing rules including Rule VI, Article 8, which allowed establishments to claim discounts as a tax deduction based on net cost and subjected implementation to Revenue Regulations of the BIR and approval by the DOF.
The DOF issued a written clarification distinguishing a tax credit under the old law from a tax deduction under R.A. No. 9257 and explained that a tax deduction reimbursed only a fractional portion of the discount in terms of foregone revenue to the government.
The DOH issued A.O. No. 171 and later A.O. No. 177 to extend the twenty percent discount to both prescription and non-prescription medicines whether branded or generic.
Petitioners alleged that their customary mark-up on branded medicines was only five percent and that granting a twenty percent discount would force sales below acquisition cost and cause capital loss.
Petitioners offered a numerical example using the drug Norvasc to show alleged per-tablet losses and asserted that only thirty-two percent of the discount would be effectively reimbursed under the tax deduction scheme.

Statutory Framework

R.A. No. 9257 amended R.A. No. 7432 and declared policies grounded in Article XV, Section 4, Article XIII, Section 11, and the Declaration of Principles and State Policies.
Section 4(a) of R.A. No. 9257 provided the grant of a twenty percent discount on medicines and permitted establishments to claim the discounts as tax deductions.
Rule VI, Article 8 of the DSWD Implementing Rules stated that the cost of the discount shall be allowed as deduction from gross income for the same taxable year and that claimed tax deductions shall be included in gross sales receipts and subject to the National Internal Revenue Code provisions.
A.O. No. 171 and A.O. No. 177 by the DOH implemented and expanded the scope of the medicine discount.
The DOF opinion explained the distinction between a tax credit and a tax deduction and illustrated the different fiscal effects under existing tax law.
Section 27(E)(4) of the NIRC was invoked to explain the definition of gross income for purposes of certain tax computations.

Contentions

Petitioners contended that Section 4(a) constituted a confiscatory taking in violation of Art. III, Sec. 9 because the tax deduction scheme did not provide just compensation.
Petitioners contended that the law violated the equal protection clause (Art. III, Sec. 1) and that the twenty percent discount on medicines offended Article XIII, Section 11 by effectively imposing burdens unevenly on small establishments.
Petitioners contended that their low mark-ups made the statutory discount unsustainable and